The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10of ECRS cases has concomitant EOM, concomitant EOM ...

Parents of children with moderate-to-severe asthma may have a much-needed treatment option: A new trial finds that an injected monoclonal antibody drug called dupilumab significantly reduces a child's ...

FRIDAY, May 23, 2025 (HealthDay News) — Dirty, crowded urban environments can significantly increase a person’s risk of developing asthma, a new study says. Cleaner, better-thought-out cities could ...

The trial aims to reassess the entrenched stepwise escalation approach to asthma care by evaluating whether earlier biologic intervention with dupilumab could offer superior outcomes compared to ...

AIM4 will randomise 250 patients with uncontrolled moderate-to-severe asthma to receive either dupilumab plus medium-dose ICS/LABA or placebo plus high-dose ICS/LABA. Credit: Angelina Avei / ...

KT-621 robustly inhibited all the tested cytokines, chemokines, cell infiltrates, and lung remodeling involved in Th2 inflammation in asthma to an extent comparable or superior to an IL-4Rα saturating ...